Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000731430 | SCV000859247 | uncertain significance | not provided | 2018-01-19 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002505067 | SCV002816710 | uncertain significance | Alagille syndrome due to a NOTCH2 point mutation; Hajdu-Cheney syndrome | 2021-12-09 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002514648 | SCV003481555 | uncertain significance | Hajdu-Cheney syndrome | 2024-01-19 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 1130 of the NOTCH2 protein (p.Gly1130Ser). This variant is present in population databases (rs782078365, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with NOTCH2-related conditions. ClinVar contains an entry for this variant (Variation ID: 134966). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt NOTCH2 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV000731430 | SCV003815998 | uncertain significance | not provided | 2021-05-05 | criteria provided, single submitter | clinical testing | |
ITMI | RCV000121716 | SCV000085914 | not provided | not specified | 2013-09-19 | no assertion provided | reference population |